Research ArticleArticle
Open Access
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
Désirée van der Heijde, Dafna D. Gladman, Mitsumasa Kishimoto, Masato Okada, Suchitrita S. Rathmann, Susan R. Moriarty, Catherine L. Shuler, Hilde Carlier, Olivier Benichou and Philip J. Mease
The Journal of Rheumatology December 2017, jrheum.170429; DOI: https://doi.org/10.3899/jrheum.170429
Désirée van der Heijde
From the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan; Eli Lilly and Company, Indianapolis, Indiana, USA; Laboratoires Lilly France, Neuilly, France; Department of Rheumatology, Swedish Medical Center; University of Washington, Seattle, Washington, USA. Funding for this study was provided by Eli Lilly and Company. D. van der Heijde has received consulting fees from AbbVie and Eli Lilly and Company. D.D. Gladman has received grants or consulting fees from AbbVie and Eli Lilly and Company. M. Kishimoto received honoraria and advisory fees from AbbVie and Eli Lilly and Company. S. Rathmann, S. Moriarty, C. Shuler, and H. Carlier are employees and stockholders of Eli Lilly and Company. O. Benichou is an employee and stockholder of Laboratoires Lilly France. P.J. Mease has received research grants and has been a consultant and/or speaker for AbbVie and Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; D.D. Gladman, MD, FRCPC, Division of Rheumatology, Department of Medicine, University of Toronto; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; S.S. Rathmann, PhD, Eli Lilly and Company; S.R. Moriarty, MD, Eli Lilly and Company; C.L. Shuler, MS, Eli Lilly and Company; H. Carlier, PhD, Eli Lilly and Company; O. Benichou, MD, PhD, MBA, Laboratoires Lilly France; P.J. Mease, MD, Department of Rheumatology, Swedish Medical Center, and University of Washington. Address correspondence to Dr. D. van der Heijde, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands. E-mail: mail@dvanderheijde.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 20, 2017.
Dafna D. Gladman
From the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan; Eli Lilly and Company, Indianapolis, Indiana, USA; Laboratoires Lilly France, Neuilly, France; Department of Rheumatology, Swedish Medical Center; University of Washington, Seattle, Washington, USA. Funding for this study was provided by Eli Lilly and Company. D. van der Heijde has received consulting fees from AbbVie and Eli Lilly and Company. D.D. Gladman has received grants or consulting fees from AbbVie and Eli Lilly and Company. M. Kishimoto received honoraria and advisory fees from AbbVie and Eli Lilly and Company. S. Rathmann, S. Moriarty, C. Shuler, and H. Carlier are employees and stockholders of Eli Lilly and Company. O. Benichou is an employee and stockholder of Laboratoires Lilly France. P.J. Mease has received research grants and has been a consultant and/or speaker for AbbVie and Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; D.D. Gladman, MD, FRCPC, Division of Rheumatology, Department of Medicine, University of Toronto; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; S.S. Rathmann, PhD, Eli Lilly and Company; S.R. Moriarty, MD, Eli Lilly and Company; C.L. Shuler, MS, Eli Lilly and Company; H. Carlier, PhD, Eli Lilly and Company; O. Benichou, MD, PhD, MBA, Laboratoires Lilly France; P.J. Mease, MD, Department of Rheumatology, Swedish Medical Center, and University of Washington. Address correspondence to Dr. D. van der Heijde, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands. E-mail: mail@dvanderheijde.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 20, 2017.
Mitsumasa Kishimoto
From the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan; Eli Lilly and Company, Indianapolis, Indiana, USA; Laboratoires Lilly France, Neuilly, France; Department of Rheumatology, Swedish Medical Center; University of Washington, Seattle, Washington, USA. Funding for this study was provided by Eli Lilly and Company. D. van der Heijde has received consulting fees from AbbVie and Eli Lilly and Company. D.D. Gladman has received grants or consulting fees from AbbVie and Eli Lilly and Company. M. Kishimoto received honoraria and advisory fees from AbbVie and Eli Lilly and Company. S. Rathmann, S. Moriarty, C. Shuler, and H. Carlier are employees and stockholders of Eli Lilly and Company. O. Benichou is an employee and stockholder of Laboratoires Lilly France. P.J. Mease has received research grants and has been a consultant and/or speaker for AbbVie and Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; D.D. Gladman, MD, FRCPC, Division of Rheumatology, Department of Medicine, University of Toronto; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; S.S. Rathmann, PhD, Eli Lilly and Company; S.R. Moriarty, MD, Eli Lilly and Company; C.L. Shuler, MS, Eli Lilly and Company; H. Carlier, PhD, Eli Lilly and Company; O. Benichou, MD, PhD, MBA, Laboratoires Lilly France; P.J. Mease, MD, Department of Rheumatology, Swedish Medical Center, and University of Washington. Address correspondence to Dr. D. van der Heijde, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands. E-mail: mail@dvanderheijde.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 20, 2017.
Masato Okada
From the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan; Eli Lilly and Company, Indianapolis, Indiana, USA; Laboratoires Lilly France, Neuilly, France; Department of Rheumatology, Swedish Medical Center; University of Washington, Seattle, Washington, USA. Funding for this study was provided by Eli Lilly and Company. D. van der Heijde has received consulting fees from AbbVie and Eli Lilly and Company. D.D. Gladman has received grants or consulting fees from AbbVie and Eli Lilly and Company. M. Kishimoto received honoraria and advisory fees from AbbVie and Eli Lilly and Company. S. Rathmann, S. Moriarty, C. Shuler, and H. Carlier are employees and stockholders of Eli Lilly and Company. O. Benichou is an employee and stockholder of Laboratoires Lilly France. P.J. Mease has received research grants and has been a consultant and/or speaker for AbbVie and Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; D.D. Gladman, MD, FRCPC, Division of Rheumatology, Department of Medicine, University of Toronto; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; S.S. Rathmann, PhD, Eli Lilly and Company; S.R. Moriarty, MD, Eli Lilly and Company; C.L. Shuler, MS, Eli Lilly and Company; H. Carlier, PhD, Eli Lilly and Company; O. Benichou, MD, PhD, MBA, Laboratoires Lilly France; P.J. Mease, MD, Department of Rheumatology, Swedish Medical Center, and University of Washington. Address correspondence to Dr. D. van der Heijde, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands. E-mail: mail@dvanderheijde.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 20, 2017.
Suchitrita S. Rathmann
From the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan; Eli Lilly and Company, Indianapolis, Indiana, USA; Laboratoires Lilly France, Neuilly, France; Department of Rheumatology, Swedish Medical Center; University of Washington, Seattle, Washington, USA. Funding for this study was provided by Eli Lilly and Company. D. van der Heijde has received consulting fees from AbbVie and Eli Lilly and Company. D.D. Gladman has received grants or consulting fees from AbbVie and Eli Lilly and Company. M. Kishimoto received honoraria and advisory fees from AbbVie and Eli Lilly and Company. S. Rathmann, S. Moriarty, C. Shuler, and H. Carlier are employees and stockholders of Eli Lilly and Company. O. Benichou is an employee and stockholder of Laboratoires Lilly France. P.J. Mease has received research grants and has been a consultant and/or speaker for AbbVie and Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; D.D. Gladman, MD, FRCPC, Division of Rheumatology, Department of Medicine, University of Toronto; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; S.S. Rathmann, PhD, Eli Lilly and Company; S.R. Moriarty, MD, Eli Lilly and Company; C.L. Shuler, MS, Eli Lilly and Company; H. Carlier, PhD, Eli Lilly and Company; O. Benichou, MD, PhD, MBA, Laboratoires Lilly France; P.J. Mease, MD, Department of Rheumatology, Swedish Medical Center, and University of Washington. Address correspondence to Dr. D. van der Heijde, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands. E-mail: mail@dvanderheijde.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 20, 2017.
Susan R. Moriarty
From the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan; Eli Lilly and Company, Indianapolis, Indiana, USA; Laboratoires Lilly France, Neuilly, France; Department of Rheumatology, Swedish Medical Center; University of Washington, Seattle, Washington, USA. Funding for this study was provided by Eli Lilly and Company. D. van der Heijde has received consulting fees from AbbVie and Eli Lilly and Company. D.D. Gladman has received grants or consulting fees from AbbVie and Eli Lilly and Company. M. Kishimoto received honoraria and advisory fees from AbbVie and Eli Lilly and Company. S. Rathmann, S. Moriarty, C. Shuler, and H. Carlier are employees and stockholders of Eli Lilly and Company. O. Benichou is an employee and stockholder of Laboratoires Lilly France. P.J. Mease has received research grants and has been a consultant and/or speaker for AbbVie and Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; D.D. Gladman, MD, FRCPC, Division of Rheumatology, Department of Medicine, University of Toronto; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; S.S. Rathmann, PhD, Eli Lilly and Company; S.R. Moriarty, MD, Eli Lilly and Company; C.L. Shuler, MS, Eli Lilly and Company; H. Carlier, PhD, Eli Lilly and Company; O. Benichou, MD, PhD, MBA, Laboratoires Lilly France; P.J. Mease, MD, Department of Rheumatology, Swedish Medical Center, and University of Washington. Address correspondence to Dr. D. van der Heijde, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands. E-mail: mail@dvanderheijde.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 20, 2017.
Catherine L. Shuler
From the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan; Eli Lilly and Company, Indianapolis, Indiana, USA; Laboratoires Lilly France, Neuilly, France; Department of Rheumatology, Swedish Medical Center; University of Washington, Seattle, Washington, USA. Funding for this study was provided by Eli Lilly and Company. D. van der Heijde has received consulting fees from AbbVie and Eli Lilly and Company. D.D. Gladman has received grants or consulting fees from AbbVie and Eli Lilly and Company. M. Kishimoto received honoraria and advisory fees from AbbVie and Eli Lilly and Company. S. Rathmann, S. Moriarty, C. Shuler, and H. Carlier are employees and stockholders of Eli Lilly and Company. O. Benichou is an employee and stockholder of Laboratoires Lilly France. P.J. Mease has received research grants and has been a consultant and/or speaker for AbbVie and Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; D.D. Gladman, MD, FRCPC, Division of Rheumatology, Department of Medicine, University of Toronto; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; S.S. Rathmann, PhD, Eli Lilly and Company; S.R. Moriarty, MD, Eli Lilly and Company; C.L. Shuler, MS, Eli Lilly and Company; H. Carlier, PhD, Eli Lilly and Company; O. Benichou, MD, PhD, MBA, Laboratoires Lilly France; P.J. Mease, MD, Department of Rheumatology, Swedish Medical Center, and University of Washington. Address correspondence to Dr. D. van der Heijde, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands. E-mail: mail@dvanderheijde.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 20, 2017.
Hilde Carlier
From the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan; Eli Lilly and Company, Indianapolis, Indiana, USA; Laboratoires Lilly France, Neuilly, France; Department of Rheumatology, Swedish Medical Center; University of Washington, Seattle, Washington, USA. Funding for this study was provided by Eli Lilly and Company. D. van der Heijde has received consulting fees from AbbVie and Eli Lilly and Company. D.D. Gladman has received grants or consulting fees from AbbVie and Eli Lilly and Company. M. Kishimoto received honoraria and advisory fees from AbbVie and Eli Lilly and Company. S. Rathmann, S. Moriarty, C. Shuler, and H. Carlier are employees and stockholders of Eli Lilly and Company. O. Benichou is an employee and stockholder of Laboratoires Lilly France. P.J. Mease has received research grants and has been a consultant and/or speaker for AbbVie and Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; D.D. Gladman, MD, FRCPC, Division of Rheumatology, Department of Medicine, University of Toronto; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; S.S. Rathmann, PhD, Eli Lilly and Company; S.R. Moriarty, MD, Eli Lilly and Company; C.L. Shuler, MS, Eli Lilly and Company; H. Carlier, PhD, Eli Lilly and Company; O. Benichou, MD, PhD, MBA, Laboratoires Lilly France; P.J. Mease, MD, Department of Rheumatology, Swedish Medical Center, and University of Washington. Address correspondence to Dr. D. van der Heijde, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands. E-mail: mail@dvanderheijde.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 20, 2017.
Olivier Benichou
From the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan; Eli Lilly and Company, Indianapolis, Indiana, USA; Laboratoires Lilly France, Neuilly, France; Department of Rheumatology, Swedish Medical Center; University of Washington, Seattle, Washington, USA. Funding for this study was provided by Eli Lilly and Company. D. van der Heijde has received consulting fees from AbbVie and Eli Lilly and Company. D.D. Gladman has received grants or consulting fees from AbbVie and Eli Lilly and Company. M. Kishimoto received honoraria and advisory fees from AbbVie and Eli Lilly and Company. S. Rathmann, S. Moriarty, C. Shuler, and H. Carlier are employees and stockholders of Eli Lilly and Company. O. Benichou is an employee and stockholder of Laboratoires Lilly France. P.J. Mease has received research grants and has been a consultant and/or speaker for AbbVie and Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; D.D. Gladman, MD, FRCPC, Division of Rheumatology, Department of Medicine, University of Toronto; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; S.S. Rathmann, PhD, Eli Lilly and Company; S.R. Moriarty, MD, Eli Lilly and Company; C.L. Shuler, MS, Eli Lilly and Company; H. Carlier, PhD, Eli Lilly and Company; O. Benichou, MD, PhD, MBA, Laboratoires Lilly France; P.J. Mease, MD, Department of Rheumatology, Swedish Medical Center, and University of Washington. Address correspondence to Dr. D. van der Heijde, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands. E-mail: mail@dvanderheijde.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 20, 2017.
Philip J. Mease
From the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University, Tokyo, Japan; Eli Lilly and Company, Indianapolis, Indiana, USA; Laboratoires Lilly France, Neuilly, France; Department of Rheumatology, Swedish Medical Center; University of Washington, Seattle, Washington, USA. Funding for this study was provided by Eli Lilly and Company. D. van der Heijde has received consulting fees from AbbVie and Eli Lilly and Company. D.D. Gladman has received grants or consulting fees from AbbVie and Eli Lilly and Company. M. Kishimoto received honoraria and advisory fees from AbbVie and Eli Lilly and Company. S. Rathmann, S. Moriarty, C. Shuler, and H. Carlier are employees and stockholders of Eli Lilly and Company. O. Benichou is an employee and stockholder of Laboratoires Lilly France. P.J. Mease has received research grants and has been a consultant and/or speaker for AbbVie and Eli Lilly and Company. D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; D.D. Gladman, MD, FRCPC, Division of Rheumatology, Department of Medicine, University of Toronto; M. Kishimoto, MD, PhD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; M. Okada, MD, Immuno-Rheumatology Center, St. Luke’s International Hospital, St. Luke’s International University; S.S. Rathmann, PhD, Eli Lilly and Company; S.R. Moriarty, MD, Eli Lilly and Company; C.L. Shuler, MS, Eli Lilly and Company; H. Carlier, PhD, Eli Lilly and Company; O. Benichou, MD, PhD, MBA, Laboratoires Lilly France; P.J. Mease, MD, Department of Rheumatology, Swedish Medical Center, and University of Washington. Address correspondence to Dr. D. van der Heijde, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands. E-mail: mail@dvanderheijde.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication September 20, 2017.
Article Figures & Data
Additional Files
Data Supplement
Files in this Data Supplement:
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
Désirée van der Heijde, Dafna D. Gladman, Mitsumasa Kishimoto, Masato Okada, Suchitrita S. Rathmann, Susan R. Moriarty, Catherine L. Shuler, Hilde Carlier, Olivier Benichou, Philip J. Mease
The Journal of Rheumatology Dec 2017, jrheum.170429; DOI: 10.3899/jrheum.170429
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
Désirée van der Heijde, Dafna D. Gladman, Mitsumasa Kishimoto, Masato Okada, Suchitrita S. Rathmann, Susan R. Moriarty, Catherine L. Shuler, Hilde Carlier, Olivier Benichou, Philip J. Mease
The Journal of Rheumatology Dec 2017, jrheum.170429; DOI: 10.3899/jrheum.170429